WO2017219510A1 - 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法 - Google Patents

一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法 Download PDF

Info

Publication number
WO2017219510A1
WO2017219510A1 PCT/CN2016/098655 CN2016098655W WO2017219510A1 WO 2017219510 A1 WO2017219510 A1 WO 2017219510A1 CN 2016098655 W CN2016098655 W CN 2016098655W WO 2017219510 A1 WO2017219510 A1 WO 2017219510A1
Authority
WO
WIPO (PCT)
Prior art keywords
chalcone
dimer compound
activity
steroidal
inflammatory
Prior art date
Application number
PCT/CN2016/098655
Other languages
English (en)
French (fr)
Inventor
唐于平
段金廒
乐世俊
Original Assignee
南京中医药大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京中医药大学 filed Critical 南京中医药大学
Publication of WO2017219510A1 publication Critical patent/WO2017219510A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Definitions

  • the present invention relates to a compound having antitumor activity, in particular to a novel compound of a steroidal chalcone carbon dimer compound having antitumor activity and anti-inflammatory activity obtained from Chinese safflower safflower and its prevention and treatment of tumor
  • a compound having antitumor activity in particular to a novel compound of a steroidal chalcone carbon dimer compound having antitumor activity and anti-inflammatory activity obtained from Chinese safflower safflower and its prevention and treatment of tumor
  • diseases and inflammatory diseases belongs to the field of medical technology.
  • the safflower is the dried flower of the genus Carthamus tinctorius L., which is contained in "Kaibao Materia Medica". It is mainly produced in Xinjiang, Henan, Zhejiang, Yunnan and other places. It has bitter taste, heart, liver, and blood circulation. It has a history of more than 2,500 years of treatment for stroke, coronary heart disease and angina pectoris as a traditional Chinese medicine for promoting blood circulation and removing blood stasis.
  • the safflower injection made from the safflower water extract is contained in the 20 volumes of the Chinese medicine prescriptions of the Ministry of Health, and is widely used in the treatment of cardiovascular diseases.
  • safflower including steroidal chalcone glycosides, flavonoids, alkaloids, organic acids and steroids, while steroidal chalcone glycosides are safflower water.
  • the main components of the extract such as hydroxysafflor yellow A (HSYA), safflower yellow A, safflomin C and dehydrated safflower yellow B (AHSYB).
  • HSYA hydroxysafflor yellow A
  • AHSYB dehydrated safflower yellow B
  • Modern pharmacological studies have found that safflower and its active ingredients have anti-coagulation, anti-oxidation, anti-inflammatory, liver-protecting, antihypertensive and other activities.
  • the invention continues to study the chemical constituent system of safflower, systematically separates the scorpion-chalcone glycoside compound in the water part, and researches and develops its new active structure.
  • the object of the present invention is to further study the chemical constituent system of safflower on the basis of the prior art, systematically separate the steroidal chalcone glycosides in the water part, and research and develop a new active structure. And through pharmacological experiments to screen its new use in the prevention and treatment of tumor diseases, inflammatory diseases and anti-thrombotic diseases.
  • a steroidal chalcone carbon dimer compound having antitumor activity and anti-inflammatory activity the structural formula of which is as shown in formula II:
  • a method for preparing a diterpenoid ketone dimer compound having antitumor activity and anti-inflammatory activity comprising the steps of:
  • step (2) taking the ethanol extract obtained in the step (1), sequentially extracting with petroleum ether, ethyl acetate and water, extracting and concentrating to obtain extracts of petroleum ether, ethyl acetate and water, respectively;
  • step (3) taking the water extract obtained in the step (2), adsorbing the resin column on the macroporous layer, eluting with water first, and then eluting with ethanol having a volume concentration of 5 to 95%, respectively, and collecting ethanol having a volume concentration of 30%.
  • the eluate is concentrated and concentrated to obtain a macroporous adsorption resin eluate;
  • the above preparation method of the steroidal chalcone carbon dimer compound having antitumor activity and anti-inflammatory activity, the extraction method of the step (1) is a percolation method, an ultrasonic extraction method, a immersion method or a reflux method. .
  • step (5) pre-HPLC chromatography separation conditions: XBridge TM C18 OBD TM Column (150 ⁇ 30 mm, 5 ⁇ m), mobile phase 0.1% formic acid water (A) and methanol (B), using a gradient elution procedure: 0-5 min, 16%-19% B; 5-15 min, 19% B; 15-20 min, 19%-44% B; 20-30 min, 44% B; 30-32 min, 44%-100% B.
  • the flow rate was 15 mL/min; the column temperature was room temperature (25 ° C).
  • steroidal chalcone carbonoside dimer compound having antitumor activity and anti-inflammatory activity for preparing an anti-inflammatory drug.
  • the anti-tumor activity and anti-inflammatory activity of the steroidal chalcone carbonoside dimer compound of the present invention is useful for preparing an antithrombotic disease.
  • the anti-tumor activity and anti-inflammatory activity of the steroidal chalcone carbonoside dimer compound of the present invention is useful for preparing an antitumor drug.
  • the tumor is lung cancer, gastric cancer, colon cancer, cervical cancer, breast cancer, liver cancer or kidney cancer.
  • the steroidal chalcone carbonoside dimer compound having antitumor activity and anti-inflammatory activity according to the present invention, the steroidal chalcone carbon dimer compound compound and a pharmaceutically acceptable carrier are prepared into tablets , capsules, injections, powder injections, granules, microcapsules, pills, ointments or transdermal controlled release dosage forms of the drug.
  • the steroidal chalcone carbon dimer compound provided by the present invention is tableted, the steroidal chalcone carbon dimer compound and lactose or corn starch are added to the lubricant magnesium stearate as needed. Mix well, granulate, and then tablet into tablets.
  • the steroidal chalcone carbon dimer compound and the carrier lactose or corn starch are uniformly mixed, granulated, and then encapsulated into capsules. Agent.
  • the oxime-type chalcone carbon dimer compound provided by the invention When used as a granule, the steroidal chalcone carbon dimer compound and the diluent lactose or corn starch are uniformly mixed, granulated and dried. Granulated.
  • the oxaquinone carbonoside dimer compound provided by the invention is prepared by preparing a powder injection and a carrier by injection into a carrier according to a conventional method.
  • the steroidal chalcone carbonoside dimer compound provided by the invention is prepared by adding a carrier to a dosage form such as a fat emulsion, an ointment or a transdermal controlled release patch according to a conventional pharmaceutical method.
  • the steroidal chalcone carbonoside dimer compound having antitumor activity and anti-inflammatory activity provided by the present invention has the following advantages as compared with the prior art:
  • the invention systematically and deeply studies the chemical constituents of safflower, and the chromatogram and mass spectrometry data analysis show that the chalcone compound is separated from safflower, and the compound represented by formula II is the first separation of the anthracene ring is 1,5-
  • the diterpenoid ketone dimers of cyclohexadienone are all novel structural compounds.
  • the anti-inflammatory and anti-tumor activity studies show that the steroidal chalcone carbon dimer compound provided by the invention has good anti-inflammatory activity and can inhibit DNA topoisomerase I, and has various tumors.
  • the anti-tumor activity and anti-inflammatory activity of the steroidal chalcone carbon dimer compound provided by the present invention is low in toxicity and can be developed into a new anti-tumor drug. Or anti-inflammatory drugs, have important application value.
  • the preparation method provided by the invention has reasonable process design and strong operability, and the prepared diterpenoid ketone dimer compound has high purity.
  • Figure 1 is a schematic view showing the structure of the diterpenoid ketone glycoside dimer compound II;
  • Figure 2 is a 1 H-NMR chart of the steroidal chalcone carbon dimer compound II
  • Figure 3 is a 13 C NMR chart of the steroidal chalcone carbon dimer compound Formula II.
  • a method for preparing a diterpenoid ketone dimer compound having antitumor activity and anti-inflammatory activity comprising the steps of:
  • step (2) taking the ethanol extract obtained in the step (1), dispersing in water, and sequentially extracting with petroleum ether and ethyl acetate. After extraction, concentration, respectively, to obtain an extract of petroleum ether, ethyl acetate and water;
  • step (4) LH-20 gel column eluate fraction 9 and fraction 3, the pre-HPLC chromatography separation, chromatographic separation pre-HPLC separation conditions: XBridge TM C18 OBD TM Column (150 ⁇ 30 mm, 5 ⁇ m), mobile phase 0.1% formic acid water (A) and methanol (B), using a gradient elution procedure: 0-5 min, 16%-19% B; 5-15 min, 19% B; 15-20 min, 19%-44% B; 20-30 min, 44% B; 30-32 min, 44%-100% B. The flow rate was 15 mL/min; the column temperature was room temperature (25 ° C).
  • H-2"" and C-1 correlations indicate that the OH-2"" and C-1 phenolic hydroxyl groups form an ester bond.
  • the phenolic hydroxyl hydrogen signal ⁇ 18.31 is related to C-1' (181.5), C-2' (106.0) and C-6' (101.4) HMBC, indicating that the compound exists as 1-enol-3,7-dione. .
  • Both anthracene rings of this compound exist in the form of 1,5-cyclohexadienone.
  • the compound exhibited a negative cotton effect at 272 nm, indicating that the absolute configuration of both 4 and 4' is S.
  • sorbitan is derived from D-glucose, the coupling constant of its end-matrix is 8.0 Hz, sorbitan is determined to be 1-dehydrated D-sorbitol, and the absolute configuration of 1′′′′ is S. .
  • the essence of blood stasis syndrome is microcirculatory disorder or abnormal blood rheology.
  • the inflammatory reaction is closely related to blood stasis syndrome, and a series of inflammatory cells and inflammatory factors are involved in the disease process of blood stasis syndrome. Therefore, this experiment used LPS-induced HUVEC to establish an in vitro inflammatory response model to evaluate the anti-inflammatory activity of steroidal chalcone glycosides.
  • HUVEC cells were purchased from Nanjing Kaiji Biotechnology Development Co., Ltd.; high glucose DEME medium and fetal bovine serum (FBS) were purchased from Gibco, USA; lipopolysaccharide (LPS) was purchased from Sigma-Aldrich, USA; TRIzol reagent was purchased from the United States. Invitrogen Corporation; PrimeScript TM RT reagent kit was purchased from China Dalian TaKaRa company.
  • FBS fetal bovine serum
  • LPS lipopolysaccharide
  • TRIzol reagent was purchased from the United States. Invitrogen Corporation
  • PrimeScript TM RT reagent kit was purchased from China Dalian TaKaRa company.
  • HUVEC cells were cultured in DMEM medium containing 10% fetal calf serum, 100 mg ⁇ mL -1 penicillin, 100 mg ⁇ mL -1 streptomycin, and placed in a 37 ° C, 5% carbon dioxide incubator. Change the culture solution for 2 to 3 days, and pass it once every 3 to 4 days.
  • HUVEC cells were seeded at 1 ⁇ 10 5 ⁇ mL -1 in six-well plates at a full volume of 2 mL per well. The experiment was divided into three groups: blank group, no LPS and drugs were added; model group, LPS was added, the final concentration was 10 ⁇ g ⁇ mL -1 , no drug was added; drug group: the compound of formula II was added in order to make formula II-1
  • the concentration of the compound was 0.8 ⁇ mol ⁇ L -1
  • the concentration of the compound of the formula II-2 was 4 ⁇ mol ⁇ L -1
  • the concentration of the compound of the formula II-3 was 20 ⁇ mol ⁇ L -1
  • the concentration of the compound of the II-4 was 100 ⁇ mol ⁇ L -1 .
  • Cells were harvested 2 days after continuous administration for extraction of total RNA.
  • RNAzol 500 ⁇ L of RNAzol to each well of a 6-well plate, prepare a 1.5 mL bullet, mark the mark, carefully scrape the cell HUVEC with a spatula and transfer to a 1.5 mL EP tube; add 500 ⁇ L of DEPC H 2 O, suspend 15s; centrifugation (13200 rpm, 10 min, 4 ° C); take 1000 ⁇ L of the supernatant into a new EP tube, centrifuge (13200 rpm, 30 min, 4 ° C); observe the RNA morphology, pour out the upper liquid, add 500 ⁇ L 70 to each EP tube.
  • RNA content (A260 / 280 range in 1.8-2.0).
  • TaKaRa Kit PrimeScript TM RT reagent Kit with gDNA Eraser
  • Nano drop was used to determine the cDNA content (A260/280 ranged from 1.6 to 1.8).
  • RNAzol one-step extraction of total RNA, 1 ⁇ g of total RNA was reverse transcribed in 10 ⁇ L system, prepare cDNA and reverse transcription PCR.
  • the chalcone carbonoside dimer compound of formula II is significantly up-regulated by the gene expression of the anti-inflammatory factor IL-10, and the diterpene compound of the formula II can be dose-dependent. Tolerantly inhibit the gene expression of IL-1, IL-6 and IFN- ⁇ , and the chalcone carbonoside dimer compound of formula II has a significant inhibitory effect on the gene expression of TNF- ⁇ at high doses, further It has been shown that the steroidal chalcone carbon dimer compound has specific anti-inflammatory activity and has the potential to be developed into a new generation of anti-inflammatory drugs.
  • Topoisomerase is an important ribozyme involved in important life activities such as DNA replication, transcription, recombination, gene regulation and cell mitosis. It can control its topology by catalyzing the breakage and binding of DNA strands.
  • Topo I content and activity are much higher than normal somatic cells, inhibiting the dissociation of Topo I-DNA cleavable complex, can selectively inhibit the rapid proliferation of tumor cells, and then kill tumor cells [8] .
  • Topo I has thus become a recognized target for anticancer drugs. Therefore, this experiment used the model of inhibiting DNA Topo I in vitro to evaluate the antitumor activity of the steroidal chalcone carbon dimer compound.
  • DNA Topo I ⁇ BR322 DNA, Agarose Regular, 6 ⁇ Loading Buffer, Tris-Borate-EDTA Buffer (TBE) powder were purchased from Bao Bio (Dalian) Co., Ltd.; 10-hydroxycamptothecin (OPT) and dodecyl Sodium sulfate was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.; Super green I was purchased from Beijing Fanbo Biochemical Co., Ltd.
  • the steroidal chalcone carbon dimer compound of the formula II prepared in Example 1 was prepared.
  • the test used a 20 ⁇ L reaction system including 10 ⁇ Topo I buffer (350 mM Tris-HCl pH 8.0, 720 mM KCI, 50 mM MgCl 2 , 50 mM DTT, 50 mM spermidine), 0.1% BSA, 0.5 ⁇ g calf thymus ⁇ BR322 DNA, 1 U Topo I.
  • the DMSO solution of the test compound, the positive drug is 10-hydroxycamptothecin (OPT).
  • the reaction was carried out in a 37 ° C metal bath for 30 min, and the reaction was terminated by adding 5 ⁇ L of a reaction stop solution of 1.5% sodium dodecyl sulfate (SDS).
  • SDS sodium dodecyl sulfate
  • Enzyme activity unit definition The amount of Topo I enzyme required to relax 0.5 ⁇ g of negative supercoiled ⁇ BR322 DNA at 37 ° C for 30 min, in units of one unit (U).
  • the compound of formula II has a significant inhibitory effect on Topo I at 100 ⁇ M, and the results indicate that the steroidal chalcone carbon dimer has good antitumor activity.
  • the present invention uses the modified MTT method to perform the in vitro anti-tumor cell experiment of the diterpenoid ketone glycoside dimer compound of the formula II prepared in the first embodiment of the present invention: lung cancer, gastric cancer, colon cancer, cervical cancer, breast cancer, liver cancer or Renal cancer was digested with trypsin and counted to prepare a cell suspension having a concentration of 5 ⁇ 10 4 /ml.
  • the experimental results show that the chalcone carbonoside dimer compound of the formula II prepared in the first embodiment of the present invention has strong inhibitory effects on lung cancer, gastric cancer, colon cancer, cervical cancer, breast cancer, liver cancer or renal cancer.
  • the inhibition rate for lung cancer, gastric cancer, colon cancer, cervical cancer, breast cancer, liver cancer or kidney cancer is more than 50%.

Abstract

一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法。所述化合物为从红花中分离得到的醌环为1,5-环己二烯酮的醌式查尔酮碳苷二聚体化合物。抗炎和抗肿瘤活性研究表明，该化合物具有抗炎活性，能抑制DNA拓扑异构酶I，对多种肿瘤具有抗肿瘤活性，且毒性实验研究表明，该醌式查尔酮与黄酮醇结合物毒性较低。

Description

一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法 技术领域
本发明涉及具有抗肿瘤活性的化合物，具体涉及从中药红花中提取的得到的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物新化合物及其在预防和治疗肿瘤疾病和炎症疾病中的用途，属医药技术领域。
背景技术
红花为菊科植物红花Carthamus tinctorius L.的干燥花，始载于《开宝本草》，主产于新疆、河南、浙江、云南等地，味辛性苦，归心、肝经，具有活血通经、散瘀止痛的功效，作为传统活血化瘀中药治疗中风、冠心病和心绞痛已有2500多年的历史。红花水提物制成的红花注射液收载于卫生部药品标准中药成方制剂二十册中，临床上广泛用于心血管疾病的治疗。目前已从红花中分离得到200多种化合物，包括醌式查尔酮苷类、黄酮类、生物碱类、有机酸类和甾体类等，而醌式查尔酮苷类是红花水提物的主要成分，如羟基红花黄色素A(HSYA)、红花黄色素A、safflomin C和脱水红花黄色素B(AHSYB)。现代药理研究发现，红花及其活性成分具有抗凝血、抗氧化、抗炎、保肝、降压等活性。
本发明继续对红花化学成分系统深入研究，对水部位中的醌式查尔酮苷类化合物进行系统分离，研究开发其新的活性结构。
发明内容
发明目的：本发明的目的是在现有技术的基础之上，对红花化学成分系统深入研究，对水部位中的醌式查尔酮苷类化合物进行系统分离，研究开发出新的活性结构，并通过药理实验筛选其在防治肿瘤疾病、炎症疾病和抗血栓疾病中的新用途。
技术方案：为了实现以上目的，本发明采取的技术方案为：
具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物，其结构式如式Ⅱ所示：
Figure PCTCN2016098655-appb-000001
具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物的制备方法，包括以下步骤：
(1)取红花，加乙醇提取得到乙醇提取液，合并提取液，浓缩，得乙醇浸膏；
(2)取步骤(1)制得的乙醇浸膏，依次用石油醚、乙酸乙酯和水进行萃取，萃取后浓缩，分别得到石油醚、乙酸乙酯和水的萃取物；
(3)取步骤(2)得到的水的萃取物，上大孔吸附树脂柱，先用水洗脱，然后分别用体积浓度为5～95％的乙醇洗脱，收集体积浓度为30％的乙醇洗脱液，浓缩，得大孔吸附树脂洗脱物；
(4)取步骤(3)得到的大孔吸附树脂洗脱物上LH-20凝胶柱层析，洗脱液为H2O-MeOH(体积比为从100∶0到0∶100)，得到30个流分；
(5)取步骤(4)LH-20凝胶柱洗脱物，上pre-HPLC色谱进行分离，得到式Ⅱ所示的醌式查尔酮碳苷二聚体化合物。
作为优选方案，以上具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物的制备方法，步骤(1)的提取方法为渗漉法，超声提取法，浸泡法或回流法。
作为优选方案，以上所述的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物的制备方法，步骤(5)pre-HPLC色谱分离的分离条件：XBridgeTM C18 OBDTM柱(150×30mm,5μm)，流动相为0.1％甲酸水(A)和甲醇(B)，采用梯度洗脱程序：0-5min，16％-19％B；5-15min，19％B；15-20min，19％-44％B；20-30min，44％B；30-32min，44％-100％B。流速为15mL/min；柱温为室温(25℃)。
本发明所述的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物在制备抗炎药物中的应用。
作为另一优选方案，本发明所述的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物在制备抗血栓性疾病中的应用。
作为另一优选方案，本发明所述的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物在制备抗肿瘤药物中的应用。所述的肿瘤为肺癌、胃癌、结肠癌、宫颈癌、乳腺癌、肝癌或肾癌。
本发明所述的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物，将醌式查尔酮碳苷二聚体化合物化合物和药学上可接受的载体制备成片剂、胶囊剂、注射剂、粉针剂、颗粒剂、微囊、丸剂、软膏剂或透皮控释贴剂剂型的药物。
将本发明提供的醌式查尔酮碳苷二聚体化合物制成片剂时，把醌式查尔酮碳苷二聚体化合物和乳糖或玉米淀粉，需要时加入润滑剂硬脂酸镁，混合均匀，整粒，然后压片制成片剂。
本发明提供的醌式查尔酮碳苷二聚体化合物制成胶囊剂时把醌式查尔酮碳苷二聚体化合物和载体乳糖或玉米淀粉混合均匀，整粒，然后装胶囊制成胶囊剂。
本发明提供的醌式查尔酮碳苷二聚体化合物制成颗粒剂时，把醌式查尔酮碳苷二聚体化合物和稀释剂乳糖或玉米淀粉、混合均匀，整粒，干燥，制成颗粒剂。
本发明提供的醌式查尔酮碳苷二聚体化合物制成粉针剂、注射液时加入载体按药学常规方法制备得到。
本发明提供的醌式查尔酮碳苷二聚体化合物制成脂肪乳剂、软膏剂或透皮控释贴剂等剂型时加入载体按药学常规方法制备得到。
有益效果：本发明提供的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物和现有技术相比具有以下优点：
本发明通过对红花化学成分进行系统深入研究，经过波谱和质谱数据分析表明从红花中分离得到查尔酮类化合物，式Ⅱ所示的化合物为首次分离得到的醌环为1,5-环己二烯酮的醌式查尔酮碳苷二聚体，都为新骨架结构化合物。且经过抗炎和抗肿瘤活性研究表明，本发明提供的醌式查尔酮碳苷二聚体化合物具有很好的抗炎活性，并且能抑制DNA拓扑异构酶I，对多种肿瘤均具有很强的抗肿瘤活性，且经过毒性实验研究表明，本发明提供的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物毒性较低，可开发成新的抗肿瘤药物或抗炎药物，具有重要的应用价值。
本发明提供的制备方法，工艺设计合理，可操作性强，制备得到的醌式查尔酮碳苷二聚体化合物纯度高。
附图说明
图1为醌式查尔酮碳苷二聚体化合物式Ⅱ的结构示意图；
图2为醌式查尔酮碳苷二聚体化合物式Ⅱ的1H-NMR图；
图3为醌式查尔酮碳苷二聚体化合物式Ⅱ的13C NMR图。
具体实施方式
根据下述实施例，可以更好地理解本发明。然而，本领域的技术人员容易理解，实施例所描述的具体的物料配比、工艺条件及其结果仅用于说明本发明，而不应当也不会限制权利要求书中所详细描述的本发明。
实施例1 醌式查尔酮碳苷二聚体化合物的制备
具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物的制备方法，包括以下步骤：
(1)取红花15kg，依次加入体积浓度为95％和70％的乙醇渗漉提取至无色，得到乙醇提取液，合并提取液，浓缩，得乙醇浸膏1950g；
(2)取步骤(1)制得的乙醇浸膏，分散在水中，依次用石油醚和乙酸乙酯进行萃取， 萃取后浓缩，分别得到石油醚、乙酸乙酯和水的萃取物；
(3)取步骤(2)得到的水的萃取物，上D101大孔吸附树脂柱，先用水洗脱，然后分别用体积浓度为5～95％的乙醇洗脱，收集体积浓度为30％的乙醇洗脱液，浓缩，得大孔吸附树脂洗脱物；
(4)取步骤(3)得到的大孔吸附树脂洗脱物上LH-20凝胶柱层析，洗脱液为H2O-MeOH(体积比为从100∶0到0∶100)，得到30个流分；
(5)取步骤(4)LH-20凝胶柱洗脱流分第9流分和第3流分，上pre-HPLC色谱进行分离，pre-HPLC色谱分离的分离条件：XBridgeTM C18 OBDTM柱(150×30mm,5μm)，流动相为0.1％甲酸水(A)和甲醇(B)，采用梯度洗脱程序：0-5min，16％-19％B；5-15min，19％B；15-20min，19％-44％B；20-30min，44％B；30-32min，44％-100％B。流速为15mL/min；柱温为室温(25℃)。
得到式Ⅱ所示的醌式查尔酮碳苷二聚体化合物，结构式如图1。
式Ⅱ所示：
Figure PCTCN2016098655-appb-000002
式Ⅱ结构解析为：暗橘色粉末，[α]D 20:+134.7(c 0.1,MeOH)。高分辨质谱(HR-ESI-MS:m/z＝1043.2679[M-H]-1,calcd.1043.2674)表明其分子式为C48H51O26。红外光谱在3433cm-1处的强吸收显示它有羟基存在，在1640cm-1处也出现羰基的特征吸收，同时在1513和1400cm-1处也出现芳环的特征吸收。紫外光谱显示228、344和420nm有最大吸收，说明分子中存在高度共轭体系。
1H-NMR(图5)显示两套对羟基桂皮酰基信号分别为δ7.51(1H,d,J＝16.0Hz)、7.19(1H,d,J＝16.0Hz)、7.39(2H,d,J＝8.5Hz)、6.76(2H,d,J＝8.5Hz)、9.70(1H,br s)，以及δ7.45(1H,d,J＝16.0Hz)、7.16(1H,d,J＝16.0Hz)、7.37(2H,d,J＝8.5Hz)、6.76(2H,d,J＝8.5Hz)。此外，在1H-NMR中还有两个碳苷葡萄糖端基氢信号δ3.78(1H,d,J＝9.0Hz)和3.57(1H,d,J＝9.5Hz)，一个脱氧山梨醇端基氢信号δ4.56(1H,d,J＝8.0Hz)，以及一些糖基氢信号δ2.9-4.6ppm。
13C-NMR(图6)显示有48个碳原子，结合1H-NMR、HSQC和精确分子量，可判定该化合物为AHSYB的同分异构体。同样，在MS/MS谱图上，该化合物裂解产生m/z 1025.25[M-H-H2O]-、923.22[M-H-C8H8O]-、593.15[M-H-C21H22O11]-和449.11[M-H-C27H30O15]-，与AHSYB裂解的特征碎片一致。
在HMBC光谱上，H-2″″和C-1相关表明OH-2″″和C-1酚羟基形成酯键。酚羟基氢信号δ18.31与C-1′(181.5)、C-2′(106.0)和C-6′(101.4)HMBC相关表明该化合物以1-烯醇-3,7-二酮形式存在。该化合物的两个醌环均以1,5-环己二烯酮形式存在。
化合物在272nm处呈现负的cotton效应，表明4和4′的绝对构型均为S。根据生源合成途径，脱水山梨醇由D-葡萄糖衍生而来，结合其端基质子的耦合常数为8.0Hz，脱水山梨醇确定为1-脱水D-山梨醇，1″″的绝对构型为S。
实施例2 抑制LPS诱导的HUVEC细胞炎症反应的活性筛选
血瘀证的本质是微循环障碍或血液流变性异常。随着细胞、分子生物学研究的深入，炎症反应与血瘀证关系密切，一系列的炎症细胞和炎症因子参与血瘀证的疾病过程。故本实验采用LPS诱导HUVEC建立体外细胞炎症反应模型评价醌式查尔酮苷类化合物的抗炎活性。
1、实验材料
1.1仪器
SERIES II WATER JAVKET型CO2孵育箱(美国Thermo公司)；1300SERIES A2型生物安全柜(美国Thermo公司)；BWS-10型水浴锅(昆山一恒仪器有限公司)；TOMY SX-500高压蒸汽灭菌锅(日本Queensland公司)；EPED超纯水系统(南京易普易达科技发展有限公司)；CKX31SF型倒置显微镜(OLYMPUS公司)；Allegra X-12R通用台式离心机(美国BECKMAN公司)；6孔培养板(美国Costar公司)；WGL-230B型电热鼓风干燥箱(天津市泰斯特仪器有限公司)；qPCR仪(美国Applied Biosystem公司)；超微量核酸蛋白检测仪(日本Queensland公司)。
1.2细胞及试剂
HUVEC细胞购自南京凯基生物科技发展有限公司；高糖DEME培养基和胎牛血清(FBS)购自美国Gibco公司；脂多糖(LPS)购自于美国Sigma-Aldrich公司；TRIzol试剂购自美国Invitrogen公司；PrimeScriptTM RT reagent kit购自中国大连TaKaRa公司。
2、实验方法
2.1细胞培养
HUVEC细胞培养于含10％的胎牛血清、100mg·mL-1青霉素、100mg·mL-1链霉素的DMEM培养基中，置于37℃、5％二氧化碳培养箱中。2～3d更换培养液，3～4d传代一次。
2.2细胞处理及分组
将HUVEC细胞按1×105个·mL-1接种于六孔板，每孔满体积2mL。实验分为3组：空白组，不加入LPS和药物；模型组，加入LPS，终浓度10μg·mL-1，不加药物；给药组：依次加入以上式Ⅱ化合物，使式式Ⅱ-1化合物浓度为0.8μmol·L-1、式Ⅱ-2化合物浓度为4μmol·L-1、式Ⅱ-3化合物浓度为20μmol·L-1、Ⅱ-4化合物浓度为100μmol·L-1药物。连续给药2天后收集细胞，用于提取总RNA。
2.3RNA提取
于6孔板每个孔各加入500μL RNAzol，准备1.5mL子弹头，标记好记号，用刮刀将细胞HUVEC仔细的刮下并且转移到1.5mL的EP管中；加入500μL DEPC H2O，混悬15s；离心(13200rpm，10min，4℃)；取上清1000μL到新的EP管中，离心(13200rpm，30min，4℃)；观察RNA形态，倾倒出上层液体，每个EP管中加入500μL 70％乙醇，离心(13200rpm，10min，4℃)；重复1次，倒置，晾干后，各加入20μL 55℃ DEPC H2O，-80℃保存；Nano drop测定RNA含量(A260/280的范围在1.8-2.0)。
2.4转cDNA
TaKaRa试剂盒：PrimeScriptTMRT reagent Kit with gDNA Eraser
1)基因组DNA去除反应
Figure PCTCN2016098655-appb-000003
2)逆转录反应
Figure PCTCN2016098655-appb-000004
Store at 4℃；
3)Nano drop测定cDNA含量(A260/280的范围在1.6-1.8)。
2.6.1.2.5 qRT-PCR SYBR Green试剂盒(QIAGEN)
1)qPCR反应体系配制
Figure PCTCN2016098655-appb-000005
2)qPCR反应程序设置
Figure PCTCN2016098655-appb-000006
取对数生长期HUVEC，加入一定浓度药物作用，利用RNAzol一步法提取总RNA，1μg的总RNA以10μL体系进行逆转录，制备cDNA并反转录PCR。使用引物如下：
Figure PCTCN2016098655-appb-000007
3、实验结果
表1 式Ⅱ醌式查尔酮苷化合物抑制LPS诱导的HUVEC细胞炎症因子表达结果
Figure PCTCN2016098655-appb-000008
与空白组相比，#P<0.05，##P<0.01，与模型组相比，*P<0.05，**P<0.01.
由以上表1实验结果表明，式Ⅱ醌式查尔酮碳苷二聚体化合物显著上调抗炎因子IL-10的基因表达作用，式Ⅱ醌式查尔酮碳苷二聚体化合物可剂量依耐性地抑制IL-1、IL-6和IFN-γ的基因表达，式Ⅱ醌式查尔酮碳苷二聚体化合物仅在高剂量浓度下对TNF-α的基因表达具有显著抑制作用，进一步表明，醌式查尔酮碳苷二聚体化合物具有特异性的抗炎活性，有开发成为新一代抗炎药的潜力。
实施例3 抑制DNA拓扑异构酶I的活性筛选
DNA拓扑异构酶(Topoisomerase)是一种重要的核酶，参与DNA复制、转录、重组、 基因调节及细胞有丝分裂等重要生命活动，可通过催化DNA链的断裂和结合控制其拓扑结构。肿瘤细胞中，Topo I含量及活性远高于正常体细胞，抑制Topo I-DNA可裂解复合物解离，就能选择性抑制肿瘤细胞的快速增殖，进而杀死肿瘤细胞[8]。Topo I由此成为公认的抗癌药作用靶点。故本实验采用体外抑制DNATopo I的模型评价醌式查尔酮碳苷二聚体化合物的抗肿瘤活性。
1、实验材料
1.1仪器
凝胶成像仪(上海培清科技有限公司)，电泳仪(北京市六一仪器厂)，金属浴(杭州博日科技有限公司)。
1.2药物及试剂
DNA Topo I、ρBR322 DNA、Agarose Regular、6×Loading Buffer、Tris-Borate-EDTA Buffer(TBE)powder均购自宝生物(大连)有限公司；10-羟基喜树碱(OPT)和十二烷基硫酸钠购自上海阿拉丁生化科技公司；Super green I购自北京泛博生物化学有限公司。实施例1制备得到的式Ⅱ醌式查尔酮碳苷二聚体化合物。
2、实验方法
该测试采用20μL反应体系，包括10×Topo I缓冲液(350mM Tris-HCl pH 8.0，720mM KCI，50mM MgCl2，50mM DTT，50mM spermidine)、0.1％BSA、0.5μg小牛胸腺ρBR322 DNA、1U Topo I、待测化合物的DMSO溶液，阳性药为10-羟基喜树碱(OPT)。置于37℃金属浴中反应30min，加入5μL反应终止液1.5％十二烷基硫酸钠(SDS)终止反应。1μL产物与2μL 6×loading buffer混合上样，1％琼脂糖凝胶、TBE缓冲液、90V电压，电泳60min。Sybr green I染色30min，凝胶成像仪观察结果，拍照记录。酶活力单位定义：能在37℃ 30min松驰0.5μg负超螺旋ρBR322 DNA所需的Topo I酶量，为1个单位(U)。
3、实验结果
式Ⅱ化合物在100μM时对Topo I有明显抑制作用，结果表明醌式查尔酮碳苷二聚体具有较好的抗肿瘤活性。
实施例4 体外抗肿瘤实验
本发明使用改良MTT法对本发明实施例1制备得到的式Ⅱ醌式查尔酮碳苷二聚体化合物进行体外抗肿瘤细胞实验：将肺癌、胃癌、结肠癌、宫颈癌、乳腺癌、肝癌或肾癌用胰酶进行消化、计数、制成浓度为5×104个/ml的细胞悬液。将96孔板中每孔加入100μl细胞悬液(每孔5×103个细胞)，然后置于37℃，5％CO2培养箱中培养24小时；用非完全培养基稀释式Ⅱ醌式查尔酮苷化合物至所需的不同梯度浓度，每孔加入100μL相应的含药培养基，同时 设立阴性对照组，溶媒对照组和阳性对照组，再将96孔板置于37℃，5％CO2培养箱中培养72小时。然后每孔加入20μL MTT(5mg/ml)，继续培养4小时，终止培养，弃去培养基，每孔加入150μL DMSO溶解，摇床10分钟轻轻混匀。在λ＝4570nm、620nm两波长下用酶标仪检测每孔的吸光度即OD值，以各复孔的平均值作为该组细胞的OD值，计算各药物的抑制率。
实验结果显示本发明实施例1制备得到的式Ⅱ醌式查尔酮碳苷二聚体化合物，对肺癌、胃癌、结肠癌、宫颈癌、乳腺癌、肝癌或肾癌均具有较强的抑制作用，在10μg/ml剂量下，对肺癌、胃癌、结肠癌、宫颈癌、乳腺癌、肝癌或肾癌抑制率均大于50％。
以上实施方式只为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人了解本发明内容并加以实施，并不能以此限制本发明的保护范围，凡根据本发明精神实质所做的等效变化或修饰，都应涵盖在本发明的保护范围内。

Claims (9)

  1. 具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物，其特征在于，其结构式如式Ⅱ所示：
    Figure PCTCN2016098655-appb-100001
  2. 具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物的制备方法，其特征在于，包括以下步骤：
    (1)取红花，加乙醇渗漉提取得到乙醇提取液，合并提取液，浓缩，得乙醇浸膏；
    (2)取步骤(1)制得的乙醇浸膏，分散在水中，依次用石油醚和乙酸乙酯进行萃取，萃取后浓缩，分别得到石油醚、乙酸乙酯和水的萃取物；
    (3)取步骤(2)得到的水的萃取物，上大孔吸附树脂柱，先用水洗脱，然后分别用体积浓度为5～95％的乙醇洗脱，收集体积浓度为30％的乙醇洗脱液，浓缩，得大孔吸附树脂洗脱物；
    (4)取步骤(3)得到的大孔吸附树脂洗脱物上LH-20凝胶柱层析，洗脱液为H2O-MeOH，体积比为从100∶0到0∶100，得到30个流分；
    (5)取步骤(4)LH-20凝胶柱洗脱流分，上pre-HPLC色谱进行分离，得到式Ⅱ所示的醌式查尔酮碳苷二聚体化合物。
  3. 具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物的制备方法，其特征在于，步骤(1)的提取方法为渗漉法，超声提取法，浸泡法或回流法。
  4. 具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物的制备方法，其特征在于，步骤(5)pre-HPLC色谱分离的分离条件：XBridgeTM C18 OBDTM柱，规格为150×30mm,5μm，流动相A相为0.1％甲酸水和B相为甲醇，采用梯度洗脱程序：0-5min，16％-19％B；5-15min，19％B；15-20min，19％-44％B；20-30min，44％B；30-32min，44％-100％B。流速为15mL/min；柱温为25℃。
  5. 根据权利要求1所述的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物， 其特征在于，将醌式查尔酮碳苷二聚体化合物化合物和药学上可接受的载体制备成片剂、胶囊剂、注射剂、粉针剂、颗粒剂、微囊、丸剂、软膏剂或透皮控释贴剂剂型的药物。
  6. 权利要求1所述的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物在制备抗炎药物中的应用。
  7. 权利要求1所述的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物在制备抗血栓性疾病中的应用。
  8. 权利要求1所述的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物在制备抗肿瘤药物中的应用。
  9. 根据权利要求8所述的具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物在制备抗肿瘤药物中的应用，其特征在于，所述的肿瘤为肺癌、胃癌、结肠癌、宫颈癌、乳腺癌、肝癌或肾癌。
PCT/CN2016/098655 2016-06-24 2016-09-12 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法 WO2017219510A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610475483.XA CN106083788B (zh) 2016-06-24 2016-06-24 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法
CN201610475483.X 2016-06-24

Publications (1)

Publication Number Publication Date
WO2017219510A1 true WO2017219510A1 (zh) 2017-12-28

Family

ID=57252791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/098655 WO2017219510A1 (zh) 2016-06-24 2016-09-12 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法

Country Status (2)

Country Link
CN (1) CN106083788B (zh)
WO (1) WO2017219510A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111362896A (zh) * 2018-12-25 2020-07-03 浙江永宁药业股份有限公司 红花黄色素及其在制备治疗心脑血管疾病药物中的应用
CN114199974A (zh) * 2021-09-30 2022-03-18 南开大学 基于同分异构体的特异性结合靶点蛋白的筛选方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108743602B (zh) * 2018-08-27 2021-02-26 滨州医学院 羟基红花黄色素b在制备治疗乳腺癌药物中的应用
CN109602737B (zh) * 2019-01-25 2021-02-19 滨州医学院 羟基红花黄色素b在制备治疗胃癌药物中的应用及药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1785988A (zh) * 2004-12-06 2006-06-14 山东绿叶天然药物研究开发有限公司 一种富含红花黄色素b的红花黄色素、制备方法和用途
US7858077B2 (en) * 2005-01-28 2010-12-28 Bezwada Biomedical Llc Functionalized phenolic esters and amides and polymers therefrom
CN105687282A (zh) * 2015-12-17 2016-06-22 北京大学 红花抗帕金森病有效部位滴丸及其制备方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HU , XIOAJIA ET AL.: "Chemical Constituents and Pharmacological Activities of CarthamusTinctorius L.", J OURNAL OF PHARMACEUTICAL PRACTICE, vol. 31, no. 3, 25 May 2013 (2013-05-25), pages 161 - 168 *
JIANG,JIANSHUANGET ET AL.: "Two New Quinochalcones from the Florets of Carthamustinctorius", ORGANIC LETTERS, vol. 12, no. 6, 19 February 2010 (2010-02-19), pages 1196 - 1199, XP055214401, ISSN: 1523-7060 *
KAZUMA, K. ET AL.: "Quinochalcones and Flavonoids from Fresh Florets in Different Cultivars of Carthamustinctorius L.", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 64, no. 8, 31 December 2000 (2000-12-31), pages 1588 - 1599, XP009186107, ISSN: 0916-8451 *
LE, SHIJUN ET AL.: "Separation and Evaluation of Antioxidant Constituents from CarthamusTinctorius", CHINA JOURNAL OF CHINESE MATERIA MEDICA, vol. 39, no. 17, 30 September 2014 (2014-09-30), pages 3295 - 3300, XP055442932, ISSN: 1001-5302 *
MESELHY, M.R. ET AL.: "Two New Quinochalcone Yellow Pigments from Carthamustinctorius and Ca2+ Antagonistic Activity of Tinctormine", CHEM. PHARM. BULL, vol. 41, 10 January 1993 (1993-01-10), pages 1796 - 1802, XP055214387, ISSN: 0009-2363 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111362896A (zh) * 2018-12-25 2020-07-03 浙江永宁药业股份有限公司 红花黄色素及其在制备治疗心脑血管疾病药物中的应用
CN111362896B (zh) * 2018-12-25 2022-10-04 浙江永宁药业股份有限公司 红花黄色素及其在制备治疗心脑血管疾病药物中的应用
CN114199974A (zh) * 2021-09-30 2022-03-18 南开大学 基于同分异构体的特异性结合靶点蛋白的筛选方法
CN114199974B (zh) * 2021-09-30 2022-08-05 南开大学 基于同分异构体的特异性结合靶点蛋白的筛选方法

Also Published As

Publication number Publication date
CN106083788B (zh) 2018-06-19
CN106083788A (zh) 2016-11-09

Similar Documents

Publication Publication Date Title
Zhao et al. Evaluation of anti-inflammatory activity of compounds isolated from the rhizome of Ophiopogon japonicas
CN105362315B (zh) 一种东革阿里提取物及其制备方法
WO2017219510A1 (zh) 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法
Cai et al. Iridoids with anti-inflammatory effect from the aerial parts of Morinda officinalis How
WO2017219509A1 (zh) 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮与黄酮醇结合物及其制备方法和应用
CN111253247B (zh) 一种具有抗炎活性的新酚酸类化合物的制备方法及应用
Yue et al. Dammarane-type triterpenoid saponins isolated from Gynostemma pentaphyllum ameliorate liver fibrosis via agonizing PP2Cα and inhibiting deposition of extracellular matrix
Liu et al. New triterpenoids from the Cyclocarya paliurus (Batalin) Iljinskaja and their anti-fibrotic activity
CN112915096B (zh) 刺囊酸-28-O-β-D-葡萄糖苷的制药用途
Wang et al. An anti-inflammatory C-stiryl iridoid from Camptosorus sibiricus Rupr.
KR101745504B1 (ko) 잠분으로부터 항암 활성을 갖는 보미폴리올 및 스티그마스테롤을 분리하는 방법
Yang et al. Antiplatelet aggregation triterpene saponins from the leaves of Ilex kudingcha
CN108341849A (zh) 玉蕊醇类三萜化合物及其制备方法和在制药中的用途
Li et al. Chemical constitutes from Tuber indicum with immunosuppressive activity uncovered by transcriptome analysis
CN110563688B (zh) 具有抗补体活性的苯并吡喃类化合物及其用途
Li et al. Saponins from Aesculus wilsonii seeds exert anti-inflammatory activity through the suppression of NF-κB and NLRP3 pathway
Li et al. New phenanthrene glycosides from Dendrobium denneanum and their cytotoxic activity
CN108623645B (zh) 一种黄酮类化合物及其制备方法与应用
AU2016101037A4 (en) Method of isolating diterpene alkaloids from aconitum carmichaelii and their use
Toussaint-Douhoré et al. Liver cancer antiproliferative activity of a new nor-cucurbitacin from Mareya micrantha Müll. Arg.
CN114533719B (zh) 松香烷型二萜类化合物在制备抗炎药物中的应用
AU2014100813A4 (en) 2&#39;-Epi-uscharin from the Latex of Calotropis gigantea with HIF-1 Inhibitory Activity
Jing et al. Three new alkaloids isolated from the stem tuber of Pinellia pedatisecta
CN112538100B (zh) 一种从黄柏中提取的具有抗炎活性的异喹啉生物碱苷类化合物及其制备方法与应用
CN114014899B (zh) 一种抗癌化合物的制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16906050

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16906050

Country of ref document: EP

Kind code of ref document: A1